These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms. Kuo FC Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973 [TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing in hematolymphoid neoplasia. Kuo FC Semin Hematol; 2019 Jan; 56(1):2-6. PubMed ID: 30573040 [TBL] [Abstract][Full Text] [Related]
12. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. Kluk MJ; Lindsley RC; Aster JC; Lindeman NI; Szeto D; Hall D; Kuo FC J Mol Diagn; 2016 Jul; 18(4):507-15. PubMed ID: 27339098 [TBL] [Abstract][Full Text] [Related]
13. Impact of next generation sequencing results on clinical management in patients with hematological disorders. Patel BJ; Barot SV; Xie Y; Cook JR; Carraway HE; Hsi ED Leuk Lymphoma; 2021 Jul; 62(7):1702-1710. PubMed ID: 33533694 [TBL] [Abstract][Full Text] [Related]
14. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600 [TBL] [Abstract][Full Text] [Related]
15. The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology. Aisner DL; Gocke CD; Jones D; Limson M; Morrissette J; Segal JP Acad Pathol; 2023; 10(3):100090. PubMed ID: 37583476 [TBL] [Abstract][Full Text] [Related]
16. Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies. Kim H; Yun JW; Lee ST; Kim HJ; Kim SH; Kim JW; Ann Lab Med; 2019 Nov; 39(6):515-523. PubMed ID: 31240878 [TBL] [Abstract][Full Text] [Related]
17. Current concepts and future directions for hemato-oncologic diagnostics. Flach J; Shumilov E; Joncourt R; Porret N; Novak U; Pabst T; Bacher U Crit Rev Oncol Hematol; 2020 Jul; 151():102977. PubMed ID: 32446181 [TBL] [Abstract][Full Text] [Related]
18. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice. Northrup V; Maybank A; Carson N; Rahmeh T Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888 [TBL] [Abstract][Full Text] [Related]
19. Genomic testing in myeloid malignancy. Docking TR; Karsan A Int J Lab Hematol; 2019 May; 41 Suppl 1():117-125. PubMed ID: 31069982 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. Aguilera-Diaz A; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Palomino-Echeverría S; Larrayoz MJ; García-Sanz R; Prieto-Conde MI; Del Carmen Chillón M; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ PLoS One; 2020; 15(1):e0227986. PubMed ID: 31978184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]